CD8A and neoplasm: In both lung and CRC murine models, BD0801, an anti-VEGF mAb, showed a significant anti-tumor capacity when combined with ICIs, whose potential mechanism is increasing CD8+ effector T cells and reducing CD8+PD-1+ exhaustion T cells [27].